Premenstrual dysphoria and the serotonin system: Pathophysiology and treatment

Journal of Clinical Psychiatry

Volumn 61, Issue SUPPL. 12, 2000, Pages 17-21

  Steiner, M ^a   Pearlstein, T ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PREGNENOLONE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

CLINICAL FEATURE; CLINICAL TRIAL; DYSPHORIA; HUMAN; MENSTRUAL CYCLE; OVARY FUNCTION; PATHOPHYSIOLOGY; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; SIDE EFFECT;

DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUOXETINE; HUMAN; PREMENSTRUAL SYNDROME; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TERMINOLOGY;

EID: 0033788486     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Mental, behavioral and developmental disorders
2. The premenstrual syndrome: A twin study
3. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression
4. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome
5. Lasting response to ovariectomy in severe intractable premenstrual syndrome
6. The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome
7. Is premenstrual dysphoric disorder a distinct clinical entity?
8. Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria
9. The measurement of premenstrual mood symptoms
10. History, evolution, and diagnosis of premenstrual dysphoric disorder
11. Implications of endocrine studies of premenstrual syndrome
12. Long-term fluoxetine treatment of late luteal phase dysphoric disorder
13. Diagnosis and assessment of premenstrual dysphoria
14. Non-antidepressant treatment of premenstrual syndrome
15. Cerebrospinal fluid levels of monoamine metabolites: A preliminary study of their relation to menstrual cycle phase, sex steroids, and pituitary hormones in healthy women and in women with PMS
16. Stress, serotonergic function, and mood in users of oral contraceptives
17. Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes
18. The role of serotonin in premenstrual syndrome
19. Female-specific mood disorders
20. 1(A) receptor subsensitivity a trait marker for late luteal phase dysphoric disorder? A pilot study
21. Serotonin and gender specific psychiatric disorders
22. Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder
23. The menstrual cycle and mood disorders
24. Depression and weight gain: The serotonin connection
25. Role of the serotonergic system in the pathogenesis of major depression and suicidal behaviour
26. Serotonin levels and platelet uptake during premenstrual tension
27. Whole blood serotonin in premenstrual syndrome
28. Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome
29. Reduced platelet tritium-labeled imipramine binding sites in women with premenstrual syndrome
30. Blunting of neuroendocrine responses to infusion of L-tryptophan in women with perimenstrual mood change
31. The neuroendocrine response to d-fenfluramine in women with premenstrual depression
32. Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder
33. Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls
34. Serotonergic dysfunction in women with pure premenstrual dysphoric disorder: Is the fenfluramine challenge test still relevant?
35. Acute tryptophan depletion aggravates premenstrual syndrome
36. Serotonin re-uptake inhibitors in the treatment of premenstrual dysphoria: Current state of knowledge
37. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects
38. Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder
39. Adrenergic receptors in premenstrual dysphoric disorder, I: Platelet α2 receptors: G(i) protein coupling, phase of menstrual cycle, and prediction of luteal phase symptom severity
40. Decreased central opioid activity in premenstrual syndrome: Luteinizing hormone response to naloxone
41. Clinical trial of naltrexone in premenstrual syndrome
42. Altered serotonergic activity in women with dysphoric premenstrual syndromes
43. Effects of the menstrual cycle on dependent variables in mood disorder research
44. State and trait serotonergic abnormalities in women with dysphoric premenstrual syndromes
45. Advances in the diagnosis and treatment of premenstrual dysphoria
46. Effect of clomipramine on premenstrual syndrome
47. Clomipramine effectively reduces premenstrual irritability and dysphoria: A placebo controlled trial
48. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: A placebo controlled trial
49. Fluoxetine in the treatment of premenstrual syndrome
50. Treatment of premenstrual syndrome with fluoxetine: An open study
51. Open trial of fluoxetine therapy for premenstrual syndrome
52. Premenstrual dysphoric disorder: Long-term treatment with fluoxetine and discontinuation
53. Sertraline versus desipramine in the treatment of premenstrual syndrome: An open-label trial
54. Sertraline efficacy in the treatment of premenstrual dysphoric disorder (PMDD)
55. Fluoxetine in the treatment of late luteal phase dysphoric disorder
56. Treatment of premenstrual syndrome with fluoxetine: A double-blind, placebo-controlled, crossover study
57. Fluoxetine treatment of severe premenstrual syndrome
58. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group
59. Fluoxetine in the treatment of premenstrual syndrome
60. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder
61. Fluoxetine in the treatment of premenstrual dysphoria
62. A double-blind trial of four medications to treat severe premenstrual syndrome
63. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: A randomized controlled trial
64. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome
65. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: A randomized, double-blind, placebo-controlled crossover trial
66. Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant
67. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: A randomized controlled trial
68. Luteal phase sertraline treatment for premenstrual dysphoric disorder: Results of a double-blind, placebo-controlled, crossover study
69. Paroxetine as a treatment for premenstrual dysphoric disorder
70. A naturalistic study of paroxetine in premenstrual syndrome: Efficacy and side-effects during 10 cycles of treatment
71. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome
72. Citalopram in premenstrual dysphoria: Is intermittent treatment during luted phases more effective than continuous medication throughout the menstrual cycle?
73. Fluvoxamine in the treatment of menstrually related mood disorders
74. Fluvoxamine for premensturual dysphoric disorder: A pilot study
75. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria
76. A naturalistic study of paroxetine in premenstrual syndrome: Efficacy and side-effects during 10 cycles of treatment
77. Fluoxetine's efficacy in improving physical symptoms associated with PMDD
78. Efficacy of fluoxetine in improving mood symptoms, physical symptoms and social impairment in patients with PMDD
79. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo
80. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes
81. Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3α, 5α-tetrahydroprogesterone (allopregnenolone) availability?
82. 4 subunit suppression prevents withdrawal properties of an endogenous steroid
83. Allopregnenolone in women with premenstrual syndrome
84. Citalopram increases pregnenolone sensitivity in patients with premenstrual syndrome: An open trial